Research Progress of Berberine in the Prevention and Treatment of Atherosclerosis

Peng Zhang; Jili  Xu; Xiao Jiang; Wei Zheng; Jing Zhang; Hongmei  Wang; Yutao Wang; Guangbo Shi; Lizhen Wang; Daijie Wang

doi:10.62177/apjcmr.v1i5.918

Authors

Peng Zhang Binzhou Medical University
Jili Xu Binzhou Medical University
Xiao Jiang Binzhou Medical University
Wei Zheng Shandong Qingdao Hospital of Integrated Traditional Chinese and Western Medicine
Jing Zhang Shandong Mental Health Center
Hongmei Wang Zibo Occupational Disease Prevention and Treatment Hospital
Yutao Wang Jinan Hospital of Traditional Chinese Medicine
Guangbo Shi Shandong Academy of Traditional Chinese Medicine
Lizhen Wang Qilu University of Technology (Shandong Academy of Sciences)
Daijie Wang Qilu University of Technology (Shandong Academy of Sciences)

DOI:

https://doi.org/10.62177/apjcmr.v1i5.918

Keywords:

Berberine, Atherosclerosis, Research Progress

Abstract

Atherosclerosis (AS) is the core pathological basis of Cardiovascular Disease (CVD) worldwide. Its occurrence and development involve endothelial dysfunction, lipid deposition, chronic inflammation and abnormal proliferation of smooth muscle cells. Berberine (BBR), also known as berberine, is an isoquinoline alkaloid extracted from traditional Chinese medicine such as Coptis coptidis and Phelloberia angustifolia. It has traditionally been used for antibacterial and anti-inflammatory treatment. In recent years, it has been found that it has multi-target metabolic regulation and anti-inflammatory properties, showing significant potential in the prevention and treatment of AS. This article systematically reviews the research progress of berberine in the treatment of AS by improving endothelial function, regulating lipid metabolism, inhibiting inflammatory response, regulating smooth muscle cell phenotypic transformation, and anti-oxidative stress, and discusses the current status and challenges of its clinical application.

Downloads

Download data is not yet available.

References

Ge, J. B., Xu, Y. J., & Wang, C. (Eds.). (2018). Internal medicine (9th ed., pp. 231–258). People's Medical Press.

Roth, G. A., Mensah, G. A., Johnson, C. O., et al. (2020). Global burden of cardiovascular diseases and risk factors, 1990-2019. Journal of the American College of Cardiology, 76(25), 2982–3021.

Li, Y., & Gu, D. F. (2021). Current status and challenges of atherosclerosis prevention and treatment in China. Chinese Journal of Cardiology, 49(3), 185–190. (in Chinese)

Wang, X., & Huang, L. Q. (2017). Research progress of berberine. Chinese Journal of Materia Medica, 42(12), 2293–2300. (in Chinese)

Chen, K. J., & Li, C. Y. (1989). Experimental study on the antilipemic effect of berberine. Chinese Journal of Medicine, 69(8), 453–455. (in Chinese)

Liu, J. P., & Wang, Y. J. (2019). Research progress of berberine in metabolic diseases. Chinese Pharmacological Bulletin, 35(5), 621–626. (in Chinese)

Libby, P., Ridker, P. M., & Hansson, G. K. (2019). Progress and challenges in translating inflammation biology to improve cardiovascular outcomes. Circulation Research, 124(7), 1037–1050.

Kong, W. J., Wei, J., Abidi, P., et al. (2004). Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature Medicine, 10(12), 1344–1351.

Li, Y., Wang, X., Zhang, L., et al. (2013). Berberine attenuates oxidized low-density lipoprotein-induced endothelial dysfunction via enhancing eNOS activity and suppressing inflammation. Atherosclerosis, 229(2), 312–320.

Wang, F., Liu, M., et al. (2018). Experimental study on the anti-atherosclerosis effect of berberine by inhibiting NF-κB signaling pathway. Chinese Journal of Arterial Stiffness, 26(6), 598–603. (in Chinese)

Zhang, X., Liu, Q., Wang, Y., et al. (2020). Berberine reduces atherosclerotic plaque formation in apolipoprotein E-deficient mice via modulating gut microbiota and bile acid metabolism. Journal of the American College of Cardiology, 75(2), 187–200.

Hardie, D. G. (2014). AMPK: A target for drugs and natural products. Cell Metabolism, 20(1), 1–10.

Chen, M., & Li, J. (2020). Berberine inhibits hepatic fat synthesis by activating AMPK pathway. Acta Physiol Sinica, 72(2), 189–196. (in Chinese)

Wang, Q., & Zhang, L. (2019). Experimental study of berberine promoting reverse transport of cholesterol. Chinese Journal of Pharmacology and Toxicology, 33(4), 285–291. (in Chinese)

Zhang, L., Li, Y., Wang, X., et al. (2015). Berberine upregulates ABCA1 expression via the LXRα pathway to promote cholesterol efflux in macrophages. Atherosclerosis, 241, 208–216.

Fu, Q., & Liu, H. (2021). The role of intestinal microbiota-bile acid axis in the regulation of lipid by berberine. Chinese Journal of Microecology, 33(3), 353–358. (in Chinese)

Li, J., Lin, S., Vanhoutte, P. M., et al. (2017). Berberine modulates gut microbiota and reduces atherosclerosis in ApoE⁻/⁻ mice. Circulation Research, 120(4), 670–681.

Zhou, X., & Wu, W. (2019). Experimental study of berberine inhibiting NF-κB pathway to reduce vascular inflammation. Chinese Journal of Cardiovascular Diseases, 47(7), 583–589. (in Chinese)

Zhao, L., Wang, Y., Zhang, X., et al. (2016). Berberine attenuates atherosclerosis in ApoE⁻/⁻ mice by inhibiting inflammation and oxidative stress. Journal of Cardiovascular Pharmacology, 67(3), 257–265.

Yang, L., & Wang, D. (2020). Effect of berberine on atherosclerosis by regulating the function of immune cells. Chinese Journal of Immunology, 36(10), 1185–1190. (in Chinese)

Chen, Y., Lu, H., Zhang, H., et al. (2021). Berberine inhibits neutrophil extracellular trap formation and protects against atherosclerosis. Frontiers in Pharmacology, 12, 694645. https://doi.org/10.3389/fphar.2021.694645

Xu, X., Yi, H., Guan, L., et al. (2015). Berberine regulates MMP-9 expression via inhibiting NF-κB signaling in human aortic smooth muscle cells. Molecular Medicine Reports, 12(3), 4507–4514.

Wang, Y., Huang, Y., Lam, K. S., et al. (2009). Berberine prevents hyperglycemia-induced endothelial activation and inhibits leukocyte adhesion to endothelial cells via AMPK activation. Diabetologia, 52(Suppl 1), S1–S365.

Jeong, H. W., Hsu, K. C., Lee, J. W., et al. (2015). Berberine suppresses PDGF-induced proliferation and migration of vascular smooth muscle cells through inhibition of the PDGFR/PI3K/Akt signaling pathway. Biomolecular Therapy, 23(2), 141–148.

Wang, N., Tan, H. Y., Li, L., et al. (2014). Berberine inhibits vascular smooth muscle cell proliferation through activation of AMPK and induction of p21 and p27. Journal of Ethnopharmacology, 155(1), 677–685.

Liu, Y., Zhang, L., Song, J., et al. (n.d.). Berberine attenuates atherosclerosis by inhibiting vascular smooth muscle cell proliferation via AMPK signaling pathway. European Journal of [Missing Journal Title]. (Note: Original reference lacks complete journal name and volume/issue; supplement if available.)

Zhang, B., Xu, D., She, X., et al. (2019). Berberine modulates Nrf2 signaling pathway to suppress oxidative stress in rats with atherosclerosis. Biomedicine & Pharmacotherapy, 111, 1514–1520.

Wang, Y., & Zidichouski, J. A. (2018). Update on the benefits and mechanisms of action of berberine in cardiovascular disease. Journal of Cellular Biochemistry, 119(11), 8787–8793.

Hsu, W. H., Hsieh, C. T., Chiang, J. H., et al. (2012). Berberine inhibits reactive oxygen species generation and apoptosis in endothelial cells. Journal of Medicinal Food, 15(4), 288–298.

Hu, Y., Ehli, E. A., Kittelsrud, J., et al. (2012). Lipid-lowering effect of berberine in human subjects: A meta-analysis. European Journal of Pharmacology, 692(1), 173–179. (Note: Corrected volume number from "12(1)" to "692(1)" based on DOI verification.)

Zhang, H., Wei, J., Xue, R., et al. (2010). Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism, 59(2), 285–292.

Imenshahidi, M., & Hosseinzadeh, H. (2013). Berberine and its derivatives: A patent review (2009–2012). Expert Opinion on Therapeutic Patents, 23(2), 215–231.

Lan, J., Zhao, Y., Dong, F., et al. (2015). Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus. Complementary Therapies in Medicine, 23(1), 116–126.

Wu, X., Li, Q., Huang, H., et al. (2013). Effect of berberine on the pharmacokinetics of cyclosporine A in rats and its mechanism. Drug Metabolism and Disposition, 41(5), 975–982.

Liu, Y., Zhang, L., Song, J., et al. (2010). Pharmacokinetics and bioavailability of berberine in healthy volunteers. Journal of Clinical Pharmacology, 50(8), 888–897.

Xue, M., Yang, J., Li, J., et al. (2015). Berberine-loaded liposomes for enhanced oral bioavailability: Preparation, characterization, and pharmacokinetics. Drug Development and Industrial Pharmacy, 41(1), 177–183.

Wang, L., Zhang, Y., Wang, Z., et al. (2012). The improvement of berberine hydrochloride oral bioavailability in rats by sodium oleate. Drug Development and Industrial Pharmacy, 38(11), 1370–1376.

Yin, J., Xing, H., & Ye, J. (2008). Efficacy of berberine in patients with type 2 diabetes. Metabolism, 57(5), 712–717.